Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591494861> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2591494861 endingPage "8523" @default.
- W2591494861 startingPage "8523" @default.
- W2591494861 abstract "8523 Background: While longer survival has been the ultimate index of better treatment in multiple myeloma, earlier endpoints have included the frequencies and durations of partial (PR) and complete remission (CR). This report describes a retrospective review with multivariate analysis of outcomes among newly diagnosed patients who received the sequence of primary chemotherapy followed by intensive therapy within the first year. Methods: Clinical outcomes were assessed in 759 consecutive patients with multiple myeloma, treated between 1987–2007, of whom 406 patients also received intensive therapy supported by autologous stem cells within the first year. Response to treatment was rated according to EBMT criteria. CR required disappearance of serum myeloma protein by immunofixation on two consecutive studies. Multiple prognostic variables were assessed in order to identify features associated with long survival. All survival times were compared by landmark analyses for those alive after 1 year, in order to avoid potential bias from the guaranteed survival of patients with responsive disease. Results: The response rate among all patients was 66% (including CR in 8%) after primary chemotherapy and then 75% after including results after high-dose therapy (including CR in 20%). The median survival for all patients was 56 months. Survival comparisons dating from 12 months after start of treatment were significantly longer for 144 patients whose disease was in CR (median 9.6 years), than for those with PR or NR (median 4.0 and 2.2 years, respectively). For those patients evaluated at 12 months, Cox regression analysis indicated that the occurrence of CR, the presence of ISS Stage I disease, and provision of intensive therapy were associated independently with long survival, in that order. Median survival times from onset of CR were similar (10–15 years) for groups of patients who achieved CR after only chemotherapy or after intensive therapy for NR, PR or as consolidation of CR. Conclusions: Survival times were similar at approximately 10–12 years for different groups of patients with CR by whatever pathway that may have been achieved. Prospective clinical trials are needed for definitive evaluation of CR as a surrogate marker for long term survival. No significant financial relationships to disclose." @default.
- W2591494861 created "2017-03-03" @default.
- W2591494861 creator A5001499416 @default.
- W2591494861 creator A5009486987 @default.
- W2591494861 creator A5027117858 @default.
- W2591494861 creator A5047673513 @default.
- W2591494861 creator A5053544656 @default.
- W2591494861 creator A5067069553 @default.
- W2591494861 creator A5091453183 @default.
- W2591494861 date "2008-05-20" @default.
- W2591494861 modified "2023-09-26" @default.
- W2591494861 title "Complete remission and survival in multiple myeloma" @default.
- W2591494861 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.8523" @default.
- W2591494861 hasPublicationYear "2008" @default.
- W2591494861 type Work @default.
- W2591494861 sameAs 2591494861 @default.
- W2591494861 citedByCount "1" @default.
- W2591494861 crossrefType "journal-article" @default.
- W2591494861 hasAuthorship W2591494861A5001499416 @default.
- W2591494861 hasAuthorship W2591494861A5009486987 @default.
- W2591494861 hasAuthorship W2591494861A5027117858 @default.
- W2591494861 hasAuthorship W2591494861A5047673513 @default.
- W2591494861 hasAuthorship W2591494861A5053544656 @default.
- W2591494861 hasAuthorship W2591494861A5067069553 @default.
- W2591494861 hasAuthorship W2591494861A5091453183 @default.
- W2591494861 hasConcept C10515644 @default.
- W2591494861 hasConcept C126322002 @default.
- W2591494861 hasConcept C141071460 @default.
- W2591494861 hasConcept C159654299 @default.
- W2591494861 hasConcept C163864487 @default.
- W2591494861 hasConcept C167135981 @default.
- W2591494861 hasConcept C203014093 @default.
- W2591494861 hasConcept C203092338 @default.
- W2591494861 hasConcept C2776364478 @default.
- W2591494861 hasConcept C2776694085 @default.
- W2591494861 hasConcept C2778808339 @default.
- W2591494861 hasConcept C38180746 @default.
- W2591494861 hasConcept C50382708 @default.
- W2591494861 hasConcept C535046627 @default.
- W2591494861 hasConcept C542903549 @default.
- W2591494861 hasConcept C71924100 @default.
- W2591494861 hasConceptScore W2591494861C10515644 @default.
- W2591494861 hasConceptScore W2591494861C126322002 @default.
- W2591494861 hasConceptScore W2591494861C141071460 @default.
- W2591494861 hasConceptScore W2591494861C159654299 @default.
- W2591494861 hasConceptScore W2591494861C163864487 @default.
- W2591494861 hasConceptScore W2591494861C167135981 @default.
- W2591494861 hasConceptScore W2591494861C203014093 @default.
- W2591494861 hasConceptScore W2591494861C203092338 @default.
- W2591494861 hasConceptScore W2591494861C2776364478 @default.
- W2591494861 hasConceptScore W2591494861C2776694085 @default.
- W2591494861 hasConceptScore W2591494861C2778808339 @default.
- W2591494861 hasConceptScore W2591494861C38180746 @default.
- W2591494861 hasConceptScore W2591494861C50382708 @default.
- W2591494861 hasConceptScore W2591494861C535046627 @default.
- W2591494861 hasConceptScore W2591494861C542903549 @default.
- W2591494861 hasConceptScore W2591494861C71924100 @default.
- W2591494861 hasIssue "15_suppl" @default.
- W2591494861 hasLocation W25914948611 @default.
- W2591494861 hasOpenAccess W2591494861 @default.
- W2591494861 hasPrimaryLocation W25914948611 @default.
- W2591494861 hasRelatedWork W2057993986 @default.
- W2591494861 hasRelatedWork W2164094466 @default.
- W2591494861 hasRelatedWork W2361700749 @default.
- W2591494861 hasRelatedWork W2381345080 @default.
- W2591494861 hasRelatedWork W2420283033 @default.
- W2591494861 hasRelatedWork W2474186635 @default.
- W2591494861 hasRelatedWork W2998733644 @default.
- W2591494861 hasRelatedWork W4200247196 @default.
- W2591494861 hasRelatedWork W573992243 @default.
- W2591494861 hasRelatedWork W1951105103 @default.
- W2591494861 hasVolume "26" @default.
- W2591494861 isParatext "false" @default.
- W2591494861 isRetracted "false" @default.
- W2591494861 magId "2591494861" @default.
- W2591494861 workType "article" @default.